Richard Vosser
Stock Analyst at JP Morgan
(1.45)
# 3,440
Out of 5,178 analysts
17
Total ratings
55.56%
Success rate
-0.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Vosser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $36.40 | - | 8 | Feb 24, 2026 | |
| MOLN Molecular Partners AG | Maintains: Neutral | $4 → $3.75 | $4.30 | -12.77% | 3 | Dec 8, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 | $7.62 | +31.23% | 1 | Dec 8, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $46.62 | - | 4 | Dec 8, 2025 | |
| NVS Novartis AG | Upgrades: Overweight | n/a | $149.70 | - | 1 | Dec 8, 2025 |
Novo Nordisk
Feb 24, 2026
Downgrades: Neutral
Price Target: n/a
Current: $36.40
Upside: -
Molecular Partners AG
Dec 8, 2025
Maintains: Neutral
Price Target: $4 → $3.75
Current: $4.30
Upside: -12.77%
Grifols
Dec 8, 2025
Maintains: Neutral
Price Target: $10
Current: $7.62
Upside: +31.23%
Sanofi
Dec 8, 2025
Downgrades: Neutral
Price Target: n/a
Current: $46.62
Upside: -
Novartis AG
Dec 8, 2025
Upgrades: Overweight
Price Target: n/a
Current: $149.70
Upside: -